Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

HEDSA discusses better services for students with disabilities
2010-09-30

At the gala dinner were, from the left: Anlia Pretorius, Chairperson of HEDSA and Head of the Disability Unit at the University of the Witwatersrand; Dr Blade Nzimande, Minister of Higher Education and Training; Ms Hetsie Veitch, Head of the Unit for Students with Disabilities at the UFS; and Prof. Niel Viljoen, Vice-Rector: Operations at the UFS.
Photo: Leonie Bolleurs

The first ever General Meeting of the Higher Education Disability Services Association (HEDSA) was held on the Main Campus of the University of the Free State (UFS) in Bloemfontein this week. HEDSA is a newly constituted body that represents the Disability Units from the various universities across the country.

The UFS is a member of HEDSA, which aims to work together to promote equal opportunities for students with disabilities in terms of access, participation and success in Higher Education.

The General Meeting forms part of the launching symposium with the theme: New Beginnings and New Directions. The symposium, attended by 15 higher education institutions in South Africa, served as a platform to explore innovative approaches to assist in improving services for students with disabilities.

Dr Blade Nzimande, Minister of Higher Education and Training, was one of the speakers at the gala dinner of this prestigious event. He said that there is still a lot of work to do to overcome discrimination against students as well as staff members with disabilities at higher education institutions. Minister Nzimande quoted from the Soudien report, a government-commissioned report that brought to light discrimination – especially racism and sexism – still endemic at South African universities. “Victims, in this instance referring to students and staff with disabilities, are denied the opportunity – either through a lack of access to opportunities or due to outright discrimination – to realise their full potential. In the process, the country is robbed of valuable but untapped human resources. Higher education institutions cause incalculable damage to South African society by failing to deal boldly with these issues. Where institutions have indeed taken action, the benefits to individuals, to the different social groups in the country, as well as to the institutions themselves, have been major.”

He stated that he believed that HEDSA as well as the symposium could play a vital role that would assist in this process.

Ms Hetsie Veitch, Head of the Unit for Students with Disabilities at the UFS, was elected as treasurer of this body for the following two years. Johnny Mokoka will represent the UFS in HEDSA’s National Student Organisation for Students with Disabilities that was established during the symposium this week.

Media Release
Issued by: Leonie Bolleurs
Strategic Communication
Tel: 051 401 2707
Sel: 0836455853
Email: bolleursl@ufs.ac.za  
30 September 2010

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept